Introduction Opzelura is the brand name of ruxolitinib cream, a topical Janus kinase inhibitor used in inflammatory and autoimmune skin diseases. It contains ruxolitinib phosphate and is available as a 1.5% cream for application to affected skin areas. Opzelura is indicated for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in … Read more
Introduction Upadacitinib is an oral Janus kinase inhibitor used in several immune-mediated inflammatory diseases. It is marketed under the brand name Rinvoq and is commonly classified as a selective JAK1 inhibitor, although it can affect other JAK enzymes at higher concentrations. Upadacitinib is used in conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic … Read more
Introduction Ruxolitinib is an oral Janus kinase inhibitor used mainly in hematological and immune-mediated disorders. It is best known by the brand name Jakafi for systemic use, and it selectively inhibits Janus kinase 1 and Janus kinase 2, commonly called JAK1 and JAK2. Ruxolitinib is important in pharmacology because JAK enzymes are central mediators of … Read more
